Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Naomi P. Moskowitz"'
Autor:
Elizabeth A. Raetz, Deepa Bhojwani, Jeffrey W. Potter, Naomi P. Moskowitz, Ilana Belitskaya-Levy, William L. Carroll, Dong Joon Min, Stephen P. Hunger, George S. Davidson, Huining Kang, Hokyung Lee, Cheryl L. Willman, Michael J. Borowitz
Publikováno v:
Blood. 108:711-717
Outcome for children with childhood acute lymphoblastic leukemia (ALL) who relapse is poor. To gain insight into the mechanisms of relapse, we analyzed gene-expression profiles in 35 matched diagnosis/relapse pairs as well as 60 uniformly treated chi
Publikováno v:
Pediatric Blood & Cancer. 46:570-578
The recent sequencing of the human genome and technical breakthroughs now make it possible to simultaneously determine mRNA expression levels of almost all of the identified genes in the human genome. DNA "chip" or microarray technology holds great p
Publikováno v:
Pediatric Blood & Cancer. 52:424-426
Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathic hemolytic anemia that is uncommon in childhood. Adults with TTP have a high mortality rate unless they are treated with plasma exchange. There are few reports of children with ac
Autor:
Martin A. Horstmann, Jeffrey W. Potter, Huining Kang, Naomi P. Moskowitz, William L. Carroll, Renée X. de Menezes, Stephen P. Hunger, Nita L. Seibel, Wenjian Yang, Deepa Bhojwani, Rob Pieters, Richard C. Harvey, Cheryl L. Willman, Elizabeth A. Raetz, Monique L. den Boer, Mary V. Relling, Harland N. Sather, Dong Joon Min
Purpose To identify children with acute lymphoblastic leukemia (ALL) at initial diagnosis who are at risk for inferior response to therapy by using molecular signatures. Patients and Methods Gene expression profiles were generated from bone marrow bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ae9bb44ab5c9c65a511bbb1b9ba186
https://europepmc.org/articles/PMC2736991/
https://europepmc.org/articles/PMC2736991/
Publikováno v:
Paediatric drugs. 9(3)
Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease. Current treatment approaches are tailored according to the clinical features of the host, genotypic features of the leukemic blast, and early response to therapy. Although these
Autor:
Naomi P. Moskowitz, Carrie Brownstein, Terzah M. Horton, Hokyung Lee, Dong Joon Min, William L. Carroll
Publikováno v:
Apoptosis : an international journal on programmed cell death. 11(11)
Cancer cell resistance to chemotherapy may be mediated by defects in apoptotic pathways. A prior study showed that in vivo apoptosis of Acute Lymphoblastic Leukemia (ALL) blasts in response to chemotherapy could occur through diverse pathways includi
Publikováno v:
American Journal of Hematology. 80:88-89
Autor:
Naomi P. Moskowitz, Elizabeth Raetz, Terzah M. Horton, Deepa Bhojwani, H. Lee, William L. Carroll, Debra J. Morrison, B. Patel
Publikováno v:
Journal of Clinical Oncology. 25:9522-9522
9522 Background: New targets for more effective, less toxic therapeutic approaches to childhood acute lymphoblastic leukemia (ALL) can be developed by discovering pathways unique to the blast. Using microarray technology, we identified potential targ
Autor:
Bret Sohn, Elizabeth A. Raetz, Hokyung Lee, Naomi P. Moskowitz, Stephen P. Hunger, Deepa Bhojwani, William L. Carroll
Publikováno v:
Blood. 106:848-848
In contrast to the excellent outcomes for children with newly diagnosed acute lymphoblastic leukemia (ALL), outcomes following ALL marrow relapse have remained poor despite incremental increases in the intensity of therapy. Those children whose relap
Autor:
Richard C. Harvey, I. Ming Chen, Jeffrey W. Potter, Yuexian Xu, Deepa Bhojwani, Edward J. Bedrick, Andrew J. Carroll, Sharon B. Murphy, Paul Helman, Kerem Ar, Robert Veroff, Susan R. Atlas, Naomi P. Moskowitz, Huining Kang, William L. Carroll, Bruce M. Camitta, Cheryl L. Willman
Publikováno v:
Blood. 106:762-762
Significant advances in the treatment of pediatric ALL have been achieved through the use of risk classification schemes that target children to increasing therapeutic intensities based on their relapse risk. However, current classification schemes d